<DOC>
	<DOCNO>NCT02267915</DOCNO>
	<brief_summary>1 . Primary endpoint : Time relapse/progression ( TTP ) achieve complete partial response ( R-GemOxD ) -induction therapy 2 . Secondary endpoint : 1 . Quality response obtain subcutaneous Rituximab maintenance . 2 . Progression-Free Survival ( PFS ) 3 . Overall Survival ( OS ) 4 . Time Next Therapy ( TTNT ) 5 . Value MRD disease outcome 6 . Toxicity</brief_summary>
	<brief_title>Phase II Efficacy Toxicity Maintenance Sub . Rituximab After Induction Relapsed MCL Non-eligible HSCT</brief_title>
	<detailed_description>This phase II trial evaluate role maintenance subcutaneous Rituximab patient stage II-IV relapsed refractory mantle-cell lymphoma complete partial response administration salvage regimen R-GemOx-D. Before study start order standardize result , R-GemOx-D salvage regimen use : Rituximab : 375 mg/m2 day 1 , Gemcitabine : 1000 mg/m2 day 2 ( 30 minute ) Oxaliplatin : 100 mg/m2 day 2 ( 3 hour ) , Dexamethasone 20 mg day 1-3 . Cycles repeat every 14 day , 8 cycle . Patients present complete partial response , salvage therapy , start study receive subcutaneous Rituximab maintenance dose : 1400 mg every 2 month 2 year ; study treatment start 6-8 week finish salvage therapy . Patients evaluate every 2 month treatment study phase every 4 month follow phase . More detail Appendix 1 ( Schedule Assessments )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Basal diagnosis mantlecell lymphoma relapse refractory . Achievement CR PR salvage therapy RGemOxD ( 6 8 cycle ) previously described45 . Age &gt; 18 year . One maximum two prior chemotherapy immunochemotherapy line . Patients consider candidate highdose chemotherapy autologous stemcell transplantation . No clinical evidence CNS involvement Signed informed consent Serum creatinine le 2 and/or bilirrubin le 2.5 UNL . Pregnant lactate woman . FCBP must agree ongoing pregnancy test course study commit use effective contraception study Prior organ transplantation . HIV positive . HBV related disease Any serious active disease comorbid medical condition ( accord investigator 's decision ) Any history cancer last 5 year , exception nonmelanoma skin tumor stage 0 cervix carcinoma . Less 50 % tumor response . Platelet count less 50 x 109/L . Neutrophil count less 1.0 x 109/L .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsed refractory patient mantle-cell lymphoma</keyword>
	<keyword>Progression high-dose chemotherapy autologous HPT</keyword>
</DOC>